Answers are grounded in this paper and cite their sources.
Lumbar facet joint osteoarthritis (FJOA) is a leading contributor to back pain, yet current administered therapies are unable to inhibit inflammatory injury of cartilage. The NLRP3 inflammasome drives the degenerative injury of cartilage by generating mature IL-1β, contributing to chondrocyte apoptosis and extracellular matrix degradation. Small‑molecule NLRP3 inhibitor CY09 holds promising anti‑inflammatory potential, but its poor aqueous solubility, insufficient cartilage penetration, and short intra‑articular residence severely restrict intra‑articular application. This study fabricated an injectable composite hydrogel (CY09@ACD/Ca-Alg) by encapsulating CY09 in cationic amino-modified β-cyclodextrin (ACD) inclusion complexes and cross-linking the complexes within a calcium-alginate network. Cy5-labelled ACD formulations showed penetration into deep layer of cartilage explants and in vivo fluorescence tracer revealed prolonged retention of the alginate matrix in rat facet joints up to 28 days. In vitro, CY09@ACD/Ca-Alg reduces NLRP3 inflammasome-associated markers, reduces mature IL-1β secretion, reduces NF-κB activation, and restores the balance between anabolic and catabolic chondrocyte phenotypes. In vivo, intra-articular injection of CY09@ACD/Ca-Alg reduces NLRP3 and Caspase-1 signals and local IL-1β levels, attenuates cartilage erosion, and decreases local inflammatory level. This composite hydrogel platform, combining host-guest solubilization, deep cartilage targeting, and sustained joint retention, provides a potential approach for FJOA.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: